KLF2 is a therapeutic target for COVID-19 induced endothelial dysfunction

• Published in: bioRxiv
• Main Authors: Xu, Suowen, Luo, Sihui, Zheng, Xueying, Weng, Jianping
• Format: Paper
• Language: English
• Published: Cold Spring Harbor Cold Spring Harbor Laboratory Press 22.02.2021; Cold Spring Harbor Laboratory
• Edition: 1.2
• Subjects: Angiogenesis; Antioxidants; Atorvastatin; Coronaviruses; COVID-19; Drug therapy; Endothelial cells; Endothelium; Fibrosis; Gene expression; IL-1β; Intercellular adhesion molecule 1; Krueppel-like factor; Microvasculature; Monocytes; Nitric oxide; Patients; Pharmacology and Toxicology; Thrombosis; Transcriptomes; Tumor necrosis factor-α; Umbilical vein; Vasodilation; COVID-19; inflammation; monocyte adhesion; endothelial dysfunction; atorvastatin; KLF2

Abstract Coronavirus disease 2019 (COVID-19) is regarded as an endothelial disease (endothelialitis) with its mechanism being incompletely understood. Emerging evidence has demonstrated that the endothelium represents the Achilles' heel in COVID-19 patients and that endothelial dysfunction prec...